Inhibrx Biosciences, Inc. — Form 8-K
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Inhibrx Biosciences secured a Second Amendment to its Loan and Security Agreement with Oxford Finance LLC (led by Oxford Finance LLC, Oxford Finance Credit Fund II LP, and Oxford Finance Credit Fund III LP) dated July 15, 2026, expanding the total credit facility from $175M drawn to $500M available. The amendment provides $100M in Term C Loans funded immediately and up to $225M in optional Term D Loans (in $50M+ increments at lenders' discretion). Inhibrx issued 21,457 warrants at $93.21/share strike (2% of Term C value) to the lenders.
Why this rating
Material debt expansion—$325M new capital is 186% of company's $174.6M market cap, providing substantial runway. Positive signal of lender confidence but increases leverage risk.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.